Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 113,400 shares, a decrease of 30.0% from the November 30th total of 162,100 shares. Based on an average daily volume of 500 shares, the days-to-cover ratio is presently 226.8 days.
Molecular Partners Stock Up 5.8 %
OTCMKTS MLLCF opened at $6.17 on Monday. Molecular Partners has a 52 week low of $5.16 and a 52 week high of $32.00. The firm's 50-day simple moving average is $6.39 and its two-hundred day simple moving average is $6.19.
Get
Molecular Partners alerts:
Molecular Partners Company Profile
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
See Also
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
分子夥伴股份公司(場外交易市場代碼:MLLCF-GET Rating)是空頭股數12月份大幅下降的目標。截至12月15日,空頭股數共有11.34萬股,比11月30日的16.21萬股減少了30.0%。以日均成交量500股計算,目前天數與回補比率為226.8天。
分子合作夥伴股票上漲5.8%
OTCMKTS MLLCF週一開盤報6.17美元。Molecal Partners的52周低點為5.16美元,52周高位為32.00美元。該公司的50日簡單移動均線切入位為6.39美元,200日簡單移動均線切入位為6.19美元。
到達
分子伴侶警報:
分子合作夥伴公司簡介
(獲取評級)
分子夥伴公司是一家臨床階段的生物製藥公司,專注於治療性蛋白質的發現、開發和商業化。它的候選產品包括用於治療新血管濕性老年性黃斑變性和糖尿病黃斑水腫的候選DARPin藥物Abempar,該藥物處於第三階段臨床試驗;以及針對SARS-CoV-2病毒的多特異性DARPin候選藥物MP0420。
另請參閱
- 免費獲取StockNews.com關於分子夥伴的研究報告(MLLCF)
- MarketBeat:回顧一週12/26-12/30
- 科技狗:是時候咬一口這些股票了
- 這筆收購會讓微軟成為熊市買入者嗎?
- 你應該暖身到Generac股票過冬嗎?
- 金塔拉治療公司是一顆隱藏的寶石嗎?
每日收到分子合作夥伴的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收分子合作夥伴和相關公司的最新新聞和分析師評級的每日摘要。